Propanc Health Group Corporation — Form 10-Q Summary
Reporting period: Three months ended September 30, 2013 (the company’s fiscal first quarter, rather than calendar 2013 Q1). The filing is unaudited. Propanc is a development-stage biotechnology company focused on cancer treatments; it reported no revenue and had no products in clinical trials or available for sale.
Financial performance and position
| Metric | Quarter ended September 30, 2013 | Comparable 2012 period / prior balance-sheet date |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $308,571 | $495,983 |
| Net loss | $571,511 | $492,681 loss |
| Comprehensive loss | $612,442 | $502,601 loss |
| Basic and diluted loss per share | $0.01 | $0.01 |
| Cash used in operations | $75,184 | $71,995 |
| Cash from financing | $113,218 | $74,544 |
| Cash at period end | $37,068 | $0 at June 30, 2013 |
| Total assets | $38,717 | $1,747 at June 30, 2013 |
| Current liabilities | $1,257,135 | $794,223 at June 30, 2013 |
| Stockholders’ deficit | $1,218,418 | $792,476 at June 30, 2013 |
With no revenue, gross profit and operating margins are not meaningful. The filing reports a working-capital deficit of $1,218,709 at September 30, 2013. It gives no clear standalone total-debt figure; current liabilities include loans, related-party balances, payables and a $403,492 warrant derivative liability. The $139,680 debenture is presented net of a debt discount, with a zero carrying amount on the balance sheet.
Material changes and notable items
- Operating expenses fell about 38% year over year, but net loss increased about 16%, chiefly reflecting a $259,251 expense from the change in fair value of warrant derivative liability.
- The company issued a $139,680 debenture on September 30, 2013, bearing 12% interest and maturing December 31, 2015. It included 3 million warrants with an initial $0.0698 exercise price subject to adjustment. The warrant liability was valued using models with significant unobservable inputs.
- Quarterly operating expenses included $159,000 of share-based expenses. No research and development expense was recorded in either comparison quarter.
- At quarter end, 71,829,768 common shares were issued and outstanding; 72,629,768 were outstanding as of November 14, 2013.
Outlook, risks and controls
- Management estimated a need for approximately $7.5 million over the next 12–24 months to fund operations and development. It expected available cash and additional financing to fund operations only until December 2013, and stated that cash was insufficient for the next 12 months. Financing was not assured; absent funding, the company might delay, reduce or cease activities.
- The filing states that substantial doubt exists about the company’s ability to continue as a going concern. Success depends on financing, development progress, patent outcomes and eventual sales; there is no assurance of profitability or adequate revenue.
- The lead product remained in preclinical development. The company was pursuing international patent protection and reported a grant in South Africa. Product development, patent acceptance and commercialization remain uncertain.
- Director and officer loans totaled $138,817 and were past due and in default; unrelated-party loans of $24,211 were also past due and in default. Director advances of $58,359 were unsecured, non-interest-bearing and due on demand.
- In October 2013, the company issued 800,000 shares to consultants and 500,000 shares as an investment-banking retainer; the retainer agreement also provides for cash and warrant success fees if capital is raised.
- Management concluded disclosure controls were ineffective because the small staff did not provide adequate segregation of duties. It planned to address the material weakness by hiring accounting personnel when resources permitted. No material control changes were reported during the quarter.
- The company reported no pending or threatened material litigation and no off-balance-sheet arrangements. Cash deposits in Australian banks were uninsured.
Investor verification points
- Confirm the company’s financing runway and whether subsequent financing was obtained, given the stated December 2013 funding horizon and going-concern uncertainty.
- Review the debenture terms, default status of other borrowings, warrant repricing provisions and valuation assumptions underlying the $403,492 derivative liability.
- Track dilution from consultant and financing-related share issuances, warrants and any later capital raising.
- Verify progress and funding for preclinical development, clinical-trial plans, and patent applications and grants across jurisdictions.
- Monitor remediation of the disclosed segregation-of-duties weakness and whether disclosure controls improve.